Petmed Express INC 8-K filings

PetMed Express, Inc. announced a definitive agreement for a sale-leaseback transaction of its headquarters and distribution center buildings for $37 million, aiming to unlock shareholder value and enhance financial flexibility.

PetMed Express, Inc. announced that director Leah A. Solivan will not stand for reelection at the 2026 annual meeting.

PetMed Express announced its fourth quarter and fiscal year 2026 financial results, reporting a decrease in net sales and a reduced net loss for the quarter, while the full year saw a significant increase in net loss.

PetMed Express announced its 2026 Annual Meeting will be held virtually on August 11, 2026, necessitating revised deadlines for shareholder proposals and director nominations.

PetMed Express, Inc. announced the successful election of its director nominees, advisory approval of executive compensation, and ratification of its independent auditor at its Annual Meeting of Shareholders on January 21, 2026.

PetMed Express, Inc. filed an amendment to clarify the effective date of its auditor dismissal and confirm no disagreements with the outgoing firm.

PetMed Express, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, replacing RSM US LLP, following a competitive process and ongoing material weaknesses in internal controls.

PetMed Express, Inc. extended its shareholder rights plan to December 2, 2026, and increased Interim Principal Financial Officer Douglas Krulik's annual base salary to $330,000, while also establishing a new severance agreement.

PetMed Express, Inc. announced preliminary Q2 2025 revenues significantly below prior year figures and received a Nasdaq notice for continued delinquency in financial filings.

PetMed Express, Inc. announced the appointment of James LaCamp as a new director and Audit Committee Chair, alongside formalizing Leslie C.G. Campbell's interim CEO employment.

PetMed Express, Inc. filed its Form 10-K for fiscal year 2025, reporting net sales below estimates and a net loss exceeding prior projections.

PetMed Express announced a $1.2 million trade name impairment, will restate past financials due to classification errors, and revealed significant governance failures and management misconduct following a whistleblower investigation.

PetMed Express, Inc. announced the approval of an annual base salary for its Interim CEO and a restricted stock award for its Chief Accounting Officer.

PetMed Express, Inc. received a Nasdaq notice for non-compliance due to delayed filing of its annual and quarterly financial reports.

PetMed Express, Inc. announced the immediate resignations of its CEO and CFO, appointing interim replacements, while an internal audit committee investigation into revenue recognition and promotional practices continues.

PetMed Express, Inc. announced the immediate resignation of Diana Garvis Purcel from its Board of Directors, leading to a reduction in board size and a new Audit Committee Chair appointment.

PetMed Express, Inc. received an expected notice from Nasdaq regarding non-compliance due to the delayed filing of its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

PetMed Express, Inc. announced a further delay in its 2025 Form 10-K filing due to an ongoing Audit Committee investigation into whistleblower reports concerning revenue recognition, a $50 coupon promotion, and the company's culture and control environment.

PetMed Express, Inc. announced preliminary fourth quarter and fiscal year 2025 results showing substantial declines in net sales and increased quarterly net loss, alongside a delay in filing its annual Form 10-K report.

PetMed Express, Inc. announced the appointment of Peter Batushansky to its Board of Directors, effective April 9, 2025, while also announcing the upcoming retirement of longtime board member Dr. Gian Fulgoni at the 2025 annual shareholders meeting.

PetMed Express reports improved Adjusted EBITDA and reduced G&A expenses in its third quarter fiscal 2025 results, signaling progress in its transformation journey.

PetMed Express files an amended 8-K report to correct technical errors in the exhibits related to the adoption of a shareholder rights plan.

PetMed Express, Inc. has implemented a limited duration shareholder rights plan to protect the company from hostile takeovers and ensure shareholders receive fair value for their investments.

PetMed Express announced improved financial results for the second quarter of fiscal year 2025, highlighted by increased net income and gross margin, as the company progresses with its business transformation.

PetMed Express, Inc. has established a new inducement incentive plan, reserving 350,000 shares for equity-based awards to attract and retain employees.

PetMed Express has appointed Robyn DElia as its new Chief Financial Officer, effective September 16, 2024, bringing over 25 years of financial leadership experience.

PetMed Express shareholders approved the 2024 Omnibus Incentive Plan and amendments to the non-employee director compensation program at the annual meeting on August 8, 2024.

PetMed Express reports a net income of $3.8 million for the first quarter of fiscal year 2025, driven by a reversal of stock compensation expense, but faces challenges with lower sales and adjusted EBITDA.

PetMed Express has appointed Doug Krulik as its new Chief Accounting Officer, effective August 19, 2024.

PetMed Express has appointed Leah Solivan, a seasoned technology entrepreneur and investor, to its Board of Directors, effective June 24, 2024.